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Background: Unlike metastatic colorectal cancer (CRC) there are to date few reports concerning the predictive
value of molecular biomarkers on the clinical outcome in stage II/III CRC patients receiving adjuvant chemotherapy.
Aim of this study was to assess the predictive value of proteins related with the EGFR- and VEGFR- signalling
cascades in these patients.
Methods: The patients' data examined in this study were from the collective of the 5-FU/FA versus 5-FU/FA/irinotecan
phase III FOGT-4 trial. Tumor tissues were stained by immunohistochemistry for VEGF-C, VEGF-D, VEGFR-3, Hif-1 α, PTEN,
AREG and EREG expression and evaluated by two independent, blinded investigators.
Survival analyses were calculated for all patients receiving adjuvant chemotherapy in relation to expression of all
makers above.
Results: Patients with negative AREG and EREG expression on their tumor had a significant longer DFS in comparison to
AREG/EREG positive ones (p< 0.05). The benefit on DFS in AREG-/EREG- patients was even stronger in the group
that received 5-FU/FA/irinotecan as adjuvant treatment (p=0.002). Patients with strong expression of PTEN profited
more in terms of OS under adjuvant treatment containing irinotecan (p< 0.05). Regarding markers of the VEGFR- pathway
we found no correlation of VEGF-C- and VEGFR-3 expression with clinical outcome. Patients with negative VEGF-D
expression had a trend to live longer when treated with 5-FU/FA (p=0.106). Patients who were negative for Hif-1
α, were disease-free in more than 50% at the end of the study and showed significant longer DFS-rates than those
positive for Hif-1 α (p=0.007). This benefit was even stronger at the group treated with 5-FU/FA/irinotecan (p=0.026).
Finally, AREG-/EREG-/PTEN+ patients showed a trend to live longer under combined treatment combination.
Conclusions: The addition of irinotecan to adjuvant treatment with 5-FU/FA does not provide OS or DFS benefit
in patients with stage II/III CRC. Nevertheless, AREG/EREG negative, PTEN positive and Hif-1 α negative patients
might profit significantly in terms of DFS from a treatment containing fluoropyrimidines and irinotecan. Our results
suggest a predictive value of these biomarkers concerning adjuvant chemotherapy with 5-FU/FA +/− irinotecan in
stage II/III colorectal cancer.
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Colorectal cancer (CRC) is the third most common ma-
lignancy and one of the most common causes of cancer-
related death in the western world [1]. The progress that
has been made over the past decades in the field of sys-
temic therapy, radiological imaging and surgical inter-
ventions resulted in a significant improvement of overall
survival (OS) rates especially in patients with distant me-
tastasis [2]. Currently, the 2-year estimated OS rates in
patients with metastatic disease reach 22% [2], whereas
patients with local advanced colorectal cancer following
adjuvant chemotherapy show a 5-year disease free sur-
vival (DFS) in 73.3% [3]. The development of new thera-
peutic strategies associated with improved OS and DFS
rates in patients with CRC is still the focus of clinical re-
search, but requires a detailed understanding of the bio-
logical processes that regulate the establishment and
progression of malignant tumors.
One of the main difficulties to establish efficient therap-
ies for human cancer is the great heterogeneity of the dis-
ease. Although many genetic and epigenetic alterations
have been identified in cancer cells, the elucidation of
their role as potential therapeutic targets remains a great
challenge. In CRC two developmental pathways represent
currently therapeutic objectives in clinical practice: the
vascular endothelial growth factor receptor- (VEGFR-)
and the epidermal growth factor receptor- (EGFR-)
pathway.
VEGF-C and VEGF-D are ligands to VEGFR-2 and
VEGFR-3 [4] and are associated with tumor growth and
metastasis in multiple cancers [5-7]. In CRC the activa-
tion of the VEGFR-3 mediated cascade leads, in crosstalk
with other intracellular pathways [8-10], to angiogenesis
and mainly to lymphangiogenesis and therefore is in-
volved in lymphatic metastasis [11-13]. In hypoxia, sur-
vival is associated with the formation of blood vessels
and is being promoted via activation of VEGF. In such
conditions the transcription factor hypoxia-inducible
factor (Hif-1) α activates a large number of genes in-
cluding VEGF via binding in its regulatory region [14].
Its role in promoting angiogenesis and invasion has
been shown in multiple cancers [15-18], whereas re-
cent studies have provided evidence of Hif-1α medi-
ated resistance to radiochemotherapy, suggesting Hif-1
α as a putative therapeutic target [19,20].
On the other hand, the stimulation of EGFR results,
through the activation of a complex network of path-
ways, including the MAPK kinase cascade and P13K/
ATK pathway, in an increased cellular proliferation,
angiogenesis and loss of apoptosis [21,22]. Amphiregulin
(AREG) and epiregulin (EREG) are, among others, li-
gands of EGFR and activate the EGFR mediated intracellu-
lar cascade [23]. Increased concentrations of both proteins
have been found in various cancers including CRC [24-26],whereas their potential therapeutic use has been suggested
in vitro and in vivo [27,28]. Similarly, the tumor suppressor
gene PTEN regulates negatively the P13K/ATK pathway
acting as a downstream effector of EGFR [29]. Inactivation
or loss of PTEN protein expression is found in up to 30%
of sporadic CRC [30,31] and is likely to be associated with
resistance to anti-EGFR monoclonal antibodies in KRAS-
wt patients [32].
In light of the high-degree of complexity and crosstalk
of the biological systems it is important to identify the
predictive factors for clinical outcomes to achieve treat-
ment optimization. In contrast to metastatic CRC, there
are to date no comparative studies that focus on a cor-
relation of VEGFR and EGFR related pathways with the
clinical outcome in patients with local advanced colon
cancer. The aim of this study was therefore to examine
and compare the effect of combined adjuvant chemo-
therapy with 5-FU/FA (folinic acid) versus the combin-
ation of 5-FU/FA and irinotecan in patients with locally
advanced colon cancer in relation to tumor VEGF-C,




The patient data examined in this study (n = 269) origin-
ate from the collective of the 5-FU/FA/irinotecan vs.
5-FU/FA trial of the German ‘Research Group Oncology
of Gastrointestinal Tumors’ (FOGT-4). Aim of the
study was to investigate the efficacy and safety of adding
irinotecan to 5-FU/FA to patients with locally advanced
colon cancer in adjuvant setting. Primary end point was
OS, and secondary end points were recurrence-free sur-
vival, toxicity, quality of life and determination of predict-
ive and prognostic makers for treatment. Eligibility criteria
were the R0-resection of a locally advanced adenocar-
cinoma of the colon in pathological UICC stage III
(pTxpNposM0R0) or IIB (pT4pN0M0R0). Patients had
to be over 18 years old and gave written informed con-
sent according to the Helsinki protocol before entering
the study, which was approved by the ethics commit-
tees of the participating institutions (Ref. Nr: #727/
2001). The study was approved by the Ethics Committee
of the University of Ulm.
Treatment
The participants were randomized into two treatment
arms. The 5-FU/FA/irinotecan group received infusional
irinotecan 80 mg/m2 over 60 minutes and FA 500 mg/m2
over 2 hours, followed by an infusion of 5-FU 2000 mg/m2
over 24 hours as previously described [33]. Patients in the
5-FU/FA therapy arm received FA 200 mg/m2 as short
intravenously (i.v) infusion combined with the i.v. adminis-
tration of 5-FU 2000 mg/m2 over 2 hours as described
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was ca. 6 months.
Immunohistochemistry
The expression of AREG, EREG, VEGF-C, VEGF-D,
VEGFR-3, PTEN and Hif-1 α was analyzed by immu-
nohistochemistry (IHC). Paraffin-embedded tissue sam-
ples were obtained from 185 patients for AREG, 183 for
EREG, 204 for VEGF-C, 203 for VEGF-D, 202 for
VEGFR-3, 115 for Hif-1 α and 122 for PTEN due to lim-
ited availability of material (Additional file 1, Table 1).
Three μm thick tissue sections were cut and mounted
on super frost slides. These were deparaffinized, rehy-
drated and peroxidase blocked (3% H2O2 in methanol,
30 min). After blocking of nonspecific protein binding
sites by using different strategies (Table 2), slides were
incubated with the respective primary antibodies AREG
and EREG (AF262 and AF1195, both R&D Systems),
VEGF-C, VEGF-D, VEGFR-3 and Hif-1α (sc-9047, sc-
13085, sc 321, sc-53546, all Santa Cruz Biotechnology,)
and PTEN (9188 s, Cell Signaling; more details in Table 2).
After incubation with secondary antibody the specificTable 1 Marker expression on tumor tissues in patients





n = 269 n = 136 (50.6%) n = 133 (49.4%)
AREG 185 94 91
negative 164 (88.6%) 84 (89.4%) 80 (87.9%)
positive 21 (11.4%) 10 (10.6%) 11 (12.1%)
EREG 183 90 93
negative 143 (78.1%) 69 (76.7%) 74 (79.6%)
positive 40 (21.9%) 21 (23.3%) 19 (20.4%)
VEGF-C 204 106 98
negative 91 (44.6%) 51 (48.1%) 40 (40.8%)
positive 113 (55.4%) 55 (51.9%) 58 (59.2%)
VEGF-D 203 106 97
negative 61 (30%) 35 (33%) 26 (26.8%)
positive 142 (70%) 71 (77%) 71 (73.2%)
VEGFR-3 202 103 99
negative 115 (56.9%) 57 (55.3%) 58 (58.6%)
positive 87 (43.1%) 46 (44.7%) 41 (41.4%)
Hif-1 alpha 115 62 53
negative 91 (79.1%) 49 (79%) 42 (79.2%)
positive 24 (20.9%) 13 (21%) 11 (20.8%)
PTEN 122 64 58
negative 74 (60.7%) 38 (59.4%) 36 (62.1%)
positive 48 (39.3%) 26 (40.6%) 22 (37.9%)antibody binding was visualized using DAB solution
(Dako, Germany). The tissues were counterstained by
hemalaun solution (Dako, Germany). Between each step
of staining the specimens were washed in DPBS.
Evaluation of staining was performed by two inde-
pendent, blinded investigators.
Statistical analysis
The staining was evaluated semiquantitatively per inten-
sity and the extent of the stained tumor area. A cut-off
of 25% stained tumor cells were considered as positive
staining for the markers. The survival analysis was per-
formed by using the Kaplan-Meier method and the log
rank test. To investigate the association between the re-
sults of immunohistochemistry obtained for all markers
and clinical-pathological parameters, univariate statis-
tical analysis were performed using Pearson’s Chi-2 test
or Fisher’s exact test.
Results
Immunohistochemical analysis in respect to groups of
treatment
As seen in Table 1 the number of tissue samples that
were stained for all markers varied between 122 -for
PTEN- and 204 -for VEGF-C. Nevertheless, there was
an equal distribution of the patients in regards of treat-
ment and positivity of markers. In the statistical analysis
of EGFR pathway 11.4%, 21.9% and 39.3% of the samples
were found positive for AREG-, EREG- and PTEN- ex-
pression respectively. Regarding the VEGFR pathway
55.4%, 70% and 43.1% of the specimens showed posi-
tivity for VEGF-C, VEGF-D and VEGFR-3. The ana-
lysis of Hif-1 α included a total of 115 tissue samples.
A positive staining for Hif-1 α was observed in 24
cases (20.9%). In Figure 1 examples of positive and
negative immunohistochemical staining are shown for
each marker.
General statistical analysis
In terms of efficacy, we detected no difference regarding
DFS and OS after the addition of irinotecan to 5-FU/FA.
Furthermore, there was no correlation between age, UICC
stage, T-, N- stage and expression of the tested markers
(data not shown).
Results for the EGFR- pathway
We found no statistically significant difference in respect
to the expression status of AREG or EREG and the sur-
vival of the patients in the total study population. How-
ever, patients with negative AREG and EREG expression
had a significant longer DFS in comparison to AREG
and EREG positive ones independent of the adjuvant
treatment (Figure 2A, p < 0.05). The OS though, did not
differ significantly (Figure 2B). Patients with a negative
Table 2 Methods for the detection of immunohistochemical expression of the tested markers
Company Antigen Blocking 1.AK 2.AK
retrieval 30′RT
AREG R&D Systems 0,1 M 5% swine 1:75, LSAB + System-HRP
AF262 EDTA buffer pH8 serum over night K 0690
EREG R&D Systems - 5% swine 1:100 LSAB + System-HRP
AF1195 serum over night K 0690
VEGF-C Sant Cruz - FFP 1:50 Dako Real™EnVision™Detection
System
sc-9047 over night K 5007
VEGF-D Sant Cruz 0.01 M FFP 1:50 Dako Real™EnVision™Detection
System
sc-13085 Citrat buffer 2 h RT K 5007
VEGFR-3 Sant Cruz 0.01 M FFP 1:100 LSAB + System-HRP
sc-321 Citrat buffer 2 h RT K 0690
Hif-1 α Sant Cruz 0,1 M 5% swine 1:50 LSAB + System-HRP
sc-53546 EDTA buffer pH8 serum over night K 0690
PTEN Cell Signaling 0.01 M 5% goat 1:75 Dako Real™EnVision™Detection
System
9188 s Citrat buffer serum over night K 5007
RT room temperature, FFP fresh frozen plasma.
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over a period of about 7 years under the combined com-
bination of 5-FU/FA/irinotecan (Figures 3A and 3B).
Patients with a negative state for AREG and EREG
benefited strongly from the addition of irinotecan in
the adjuvant backbone treatment, in terms of DFS over
80 months (Figure 3C, p = 0.002). The median DFS for
AREG- and EREG- positive patients was 45 months
under 5-FU/FA/irinotecan, whereas more than half of
the patients with negative immunohistochemistry for
AREG and EREG were disease free at the end of theFigure 1 Immunochistochemistry for AREG, EREG, Hif-1 α, VEGF-C, VEG
with stage II/III CRC. According to the intensity and extend the stained tustudy. Furthermore, PTEN expression appeared to have
no significant impact on the survival rates of the total
study population (Figure 4A). However, in the group of
5-FU/FA/irinotecan patients positive for PTEN bene-
fited in terms of OS compared to PTEN- negative ones
(p < 0.05, Figure 4B).
Results for the VEGFR- pathway
The expression of VEGF-D, VEGF-C and VEGFR-3 in
tumor tissues did not show a direct impact on survival
in the total study population. In the 7-year survival, aF-D, VEGFR-3 and PTEN in tumour tissues obtained from patients
mor area samples were classified as positive or negative.
Figure 2 Survival analysis in patients receiving adjuvant treatment in relation to AREG- and EREG- expression. A. Disease-free survival rates.
B. overall survival rates.
Figure 3 Survival analysis in patients under adjuvant 5-FU/FA/irinotecan in relation to AREG/EREG- expression. A. Disease-free survival in
relation to AREG expression on tumor tissues. B. Disease-free survival in relation to EREG expression on tumor tissues. C. Disease-free survival in
relation to AREG and EREG expression on tumor tissues.
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Figure 4 Overall survival analysis for patients according to tumor PTEN-status. A. in the whole population B. in the subgroup treated with
adjuvant 5-FU/FA/irinotecan.
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VEGF-D expression (p = 0.155, Figure 5A). While VEGF-
D negative patients showed a trend to remain disease free
towards treatment with 5-FU/FA (p = 0.106, Figure 5B),
no benefit in survival was observed under the combined
adjuvant treatment (Figure 5C).
In respect to Hif-1 α, the median DFS of patients
with positive status was 3.3 years for the entire group,
2.1 years for the 5-FU/FA group and 3.9 years for the
5-FU/FA/irinotecan group. Patients who were negative
for Hif-1 α, were in more than 50% disease-free at the
end of the examination period in all above cases (p = 0.007,
p = 0.059 and p = 0.026 respectively, Figure 6).
Combining results for both pathways
Patients who had a negative expression for AREG, EREG,
Hif-1 α and positive for PTEN represented 9% of the
total study population and showed not significant pro-
longed OS and DFS under 5-FU/FA/irinotecan treatment
(Figure 7A). 34 patients were AREG-/EREG-/PTEN+ and
had a trend to live longer under the triple combination
(p = 0.071, Figure 7B).
Discussion
There is an increasing number of reports concerning the
role of biomarkers on the identification of those patients
who will benefit from treatment with targeted agents
[35-38]. In this study we evaluated the impact of the
tyrosine kinase receptor ligands VEGF-C, -D, AREG,
EREG, as well as Hif-1 α, PTEN and of the VEGFR-3 on
disease recurrence and survival in patients with CRC re-
ceiving adjuvant chemotherapy. This is –to our knowledge-
the first study analyzing all these parameters in the specific
target population of CRC stage II/III.
Indeed, unlike metastatic CRC, there have been only a
limited number of trials that attempted to determineprognostic and predictive biomarkers in resected CRC.
Current evidence suggests that the presence of high
microsatellite instability (MSI-h) in tumor tissues is as-
sociated with a longer DFS and OS in non-metastatic
CRC [33,39-41]. The ongoing B-CAST trial [42] evalu-
ates the protein expression of thymidine phosphorylase
(TP), dihydropyrimidine dehydrogenase (DPD), EGFR
and VEGF in 2128 patients with stage III CRC, but
the results are yet to be published. Other studies pro-
posed loss of SMAD4 [43], high expression of wt-p53
[44], NF-kB negativity or JNK positivity [45] as pos-
sible biomarkers associated with longer time to re-
lapse in stage II/III CRC. Nevertheless, there has been
so far no sufficient validation of their use in clinical
practice.
Similarly to the findings of Tikidzhieva et al. [33] we
observed in our analysis no benefit of the addition of iri-
notecan to adjuvant 5-FU/FA in terms of DFS and OS
(data not shown). These results are consistent with those
of previously published phase III trials [46-48]. Never-
theless, we cannot exclude the possibility that irinotecan
might be effective for subgroups of patients with stage
II/III CRC whose tumors present specific molecular
patterns.
As depicted in Table 1 the tumor tissues in our study
showed higher levels of VEGF-C, VEGF-D, VEGFR-3 ex-
pression when compared to proteins related to the EGFR
pathway. Nevertheless, these expression levels should
not be considered representative since they may vary
among tumors with different entity and TNM stage. It is
characteristic, that the immunohistochemical detection
of VEGF-C and VEGF-D in stage II/III colorectal adeno-
carcinoma varies between 43%-77% and 50%-64% [49,50]
respectively.
In our study we demonstrated a statistical significant
benefit in terms of DFS for patients who lacked AREG
Figure 5 Disease-free survival in patients under adjuvant 5-FU/FA versus 5-FU/FA/irinotecan in relation to VEGF-D expression.
A. Disease-free survival rates in the total population, B. Patients under adjuvant 5-FU/FA, C. Patients under adjuvant 5-FU/FA/irinotecan.
Thomaidis et al. Journal of Experimental & Clinical Cancer Research 2014, 33:83 Page 7 of 11
http://www.jeccr.com/content/33/1/83and EREG expression. This benefit was even stronger
when AREG-/EREG- patients received adjuvant therapy
including irinotecan (Figure 3). Our findings are consist-
ent with those of Jacobs et al. who postulated that ex-
pression of AREG/EREG can predict the outcome for
KRAS wt stage IV CRC when treated with cetuximab
and irinotecan [51]. In this study a positive prognosis as-
sociated with AREG/EREG expression for EGFR targeted
treatment was shown. This discrepancy in comparison
to our results might be attributed to the applied treat-
ment with anti-EGFR agents or to the metastasized stage
of the examined patients in Jacobs’ study. Indeed, EGFR
blockage for stage II/III CRC patients under adjuvant
treatment has not been proven beneficial so far [52].
Furthermore, the RAS-status was not tested in our study
since the limited number of samples in the tested sub-
groups might lead to false interpretations.
Emerging data from in vitro studies with gastric [53]
and colorectal [54] cancer cell lines demonstrated a syn-
ergistic effect of EGFR-inhibitors and irinotecan. Yashiroet al. showed that EGFR-inhibition could enhance the
activity of SN-38, an active metabolite of irinotecan,
in SN-38 resistant gastric cancer cell lines [53]. They
proposed a down-regulation of SN-38 metabolism re-
lated genes through EGFR-inhibition, which might
also explain the longer DFS of AREG and EREG
negative patients under irinotecan treatment in our
study.
Enhancement of SN-38 efficacy has also been demon-
strated in ovarian cancer cells that had high PTEN ex-
pression [55]. Herein the proposed mechanism was a
synergistic inhibition of topoisomerase-I activity. In deed,
in our study PTEN + patients treated with 5-FU/FA/irino-
tecan had significant longer OS than PTEN- patients,
which has also been shown from our group in advanced
gastric cancer before [56].
In the last part of our study we examined whether pro-
teins of the VEGFR- pathway could play a predictive role to
adjuvant chemotherapy in patients with CRC UICC II and
III. We noticed a trend for a longer DFS in VEGF-D
Figure 6 Disease-free survival in patients under adjuvant 5-FU/FA versus 5-FU/FA/irinotecan in relation to Hif-1 α expression.
A. Disease-free survival rates in the total population, B. Patients under adjuvant 5-FU/FA, C. Patients under adjuvant 5-FU/FA/irinotecan.
Figure 7 Survival analysis in relation to collective biomarker expression. Overall survival in patients treated with adjuvant 5-FU/FA versus
5-FU/FA/irinotecan in patients negative for AREG, EREG, Hif-1 α and positive for PTEN (A) and in patients negative for AREG, EREG and positive
for PTEN (B).
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(Figure 5B). A further relation of VEGF-C or VEGF-R3
with the survival of patients was not observed. These
results are consistent with the findings of the AVANT
and NSABP C08 trials published previously [57,58].
Both of these trials reported no benefit from the addition
of bevacizumab to the combination of fluoropyrimidines
and oxaliplatin in the adjuvant treatment of stage II/III
CRC. Regarding Hif-1 α expression on tumor tissues
we demonstrated a statistically significant prolonged
DFS for patients with negative Hif-1 α expression, es-
pecially for those under irinotecan treatment. In agree-
ment with previous in vitro and in vivo models [59] we
showed that the anti-tumor efficacy of irinotecan is
stronger when Hif-1 α on tumor tissues is down regu-
lated. Since irinotecan inhibits the accumulation of
Hif-1 α [60,61], our findings suggest a further mechan-
ism of interaction between cytotoxicity of irinotecan
and Hif-1 α.
In the subgroup of AREG-/EREG-/Hif-1 α-/PTEN +
patients we found a non statistically significant survival
benefit under the combined treatment combination. The
lack of significance could be attributed to the small
number of patients with the specific biomarker combin-
ation. However, AREG-/EREG-/PTEN + patients showed
a clear trend to profit from the addition of irinotean to
the adjuvant regime (Figure 7).
Conclusions
There is an increasing interest in personalized therapy
for colon cancer patients receiving adjuvant therapy.
This is -to our knowledge- the first study investigating the
role of multiple biomarkers of the EGFR- and VEGFR-
pathway on the treatment outcome in patients with stage
II/III CRC. We showed that an adjuvant therapy contain-
ing irinotecan might be beneficial for AREG/EREG
negative, PTEN positive and Hif-1 α negative patients.
However, the decision of the adjuvant regime should
be always based upon the clinical characteristics of the
patients including age, pre-existing treatment and side
effects (i.e. oxaliplatin induced neuropathy). Neverthe-
less, further prospective studies including a large num-
ber of patients with stage II/III CRC are necessary in
order to evaluate which molecular patterns might serve
as predictive markers for treatment outcome in these
patients.
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